Franklin Biotechnology Discv C(acc)USD |
Performance History | 31/03/2024 |
Growth of 1,000 (EUR) |
Fund | 16.3 | -11.6 | -7.3 | 12.7 | 14.3 | |
+/-Cat | -2.9 | -8.6 | 5.5 | 11.6 | 10.6 | |
+/-Idx | -9.5 | -18.5 | -4.3 | 2.8 | 4.4 | |
Category: Sector Equity Biotechnology | ||||||
Benchmarks: Morningstar Gbl Biotechnolo... |
Key Stats | ||
NAV 18/04/2024 | USD 44.20 | |
Day Change | -1.73% | |
Morningstar Category™ | Sector Equity Biotechnology | |
ISIN | LU0260873095 | |
Fund Size (Mil) 31/03/2024 | USD 1785.11 | |
Share Class Size (Mil) 18/04/2024 | USD 11.26 | |
Max Initial Charge | - | |
Ongoing Charge 04/03/2024 | 2.39% |
Morningstar Research |
Analyst Report | 13/10/2023 Katie Rushkewicz Reichart, Director Morningstar, Inc |
Franklin Biotechnology Discovery is overseen by experienced managers, but limited resources and an undifferentiated process earn the fund a Morningstar Analyst Rating of Neutral.This strategy’s compact team is composed of three managers who have... | |
Click here to read this analyst report |
Morningstar Pillars | |
---|---|
People | 23 |
Parent | 23 |
Process | 23 |
Performance | |
Price |
Investment Objective: Franklin Biotechnology Discv C(acc)USD |
The Fund’s investment objective is capital appreciation. |
Returns | |||||||||||||
|
Management | ||
Manager Name Start Date | ||
Evan McCulloch 01/11/2000 | ||
Wendy Lam 01/09/2018 | ||
Click here to see others | ||
Inception Date 01/09/2006 |
Advertisement |
Benchmarks | |
Fund Benchmark | Morningstar Benchmark |
NASDAQ Biotechnology TR USD | Morningstar Gbl Biotechnology NR USD |
Target Market | ||||||||||||||||||||
|
Portfolio Profile for Franklin Biotechnology Discv C(acc)USD | 31/03/2024 |
|
|
Top 5 Holdings | Sector | % |
Amgen Inc | Healthcare | 6.85 |
Regeneron Pharmaceuticals Inc | Healthcare | 6.43 |
Vertex Pharmaceuticals Inc | Healthcare | 5.34 |
Ascendis Pharma A/S ADR | Healthcare | 4.22 |
Gilead Sciences Inc | Healthcare | 3.07 |
Increase Decrease New since last portfolio | ||
Franklin Biotechnology Discv C(acc)USD |